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. PRDM16 (PR domain containing 16) is a 140 kDa zinc finger protein that robustly induces brown fat determination and differentiation 2 . Recent data suggests that brown fat cells arise in vivo from a Myf5-positive, myoblastic lineage by the action of PRDM16 (ref. 3) ; however, the molecular mechanisms responsible for this developmental switch is unclear. Here we show that PRDM16 forms a transcriptional complex with the active form of C/EBP-b (also known as LAP), acting as a critical molecular unit that controls the cell fate switch from myoblastic precursors to brown fat cells. Forced expression of PRDM16 and C/EBP-b is sufficient to induce a fully functional brown fat program in naive fibroblastic cells, including skin fibroblasts from mouse and man. Transplantation of fibroblasts expressing these two factors into mice gives rise to an ectopic fat pad with the morphological and biochemical characteristics of brown fat. Like endogenous brown fat, this synthetic brown fat tissue acts as a sink for glucose uptake, as determined by positron emission tomography with fluorodeoxyglucose. These data indicate that the PRDM16-C/EBP-b complex initiates brown fat formation from myoblastic precursors, and may provide opportunities for the development of new therapeutics for obesity and type-2 diabetes.
Because of the importance of brown adipose tissue (BAT) as a natural defence against hypothermia and obesity 1 , and its demonstrated presence in adult humans [4] [5] [6] [7] , understanding its formation in mechanistic detail may open new avenues to the development of new therapeutics for metabolic diseases such as obesity and type-2 diabetes. Several transcriptional regulators have been identified that positively or negatively control BAT development including RB1 (ref. 8) , p107 (also known as RBL1) 9 , RIP140 (NRIP1) 10 and FOXC2 (ref. 11) . Most recently, we have shown that PRDM16, a 140-kDa zinc finger protein, functions as a bidirectional switch in brown fat cell fate by stimulating the development of brown fat cells from white preadipocytes 12, 13 and from Myf5-positive myoblastic precursors 3 in vitro and in vivo. At a molecular level, PRDM16 works as a transcriptional co-regulatory protein by co-activating PPARc (peroxisome proliferator-activated receptor c), which is considered the 'master' gene of fat cell differentiation 14, 15 , and this is almost certainly an important event in the conversion of myoblasts to brown adipocytes 3 . However, both isoforms of PPARc are expressed at very low levels in primary and immortalized myoblasts, whereas they are abundantly expressed in white and brown preadipocytes ( Supplementary Fig. 1 ). Hence, it is very likely that PRDM16 initiates the process of myoblast to brown fat conversion by complexing with other DNA-binding factors, well before the coactivation of PPARc.
We therefore devised a strategy to address this, as illustrated in Fig. 1a . In brief, we performed proteomic analyses of transcriptional complexes formed with wild-type PRDM16 or different mutant alleles that were differentiation-competent or -incompetent. Transcription factors that co-purified preferentially with differentiationcompetent PRDM16 proteins were identified; their expression in white and brown fat was then analysed and compared to that of PRDM16. Subsequently, we examined their function in the process of myoblast to brown fat conversion through PRDM16.
As shown in Fig. 1b , wild type PRDM16 and a mutant protein lacking the PR (PRD1-BF1-RIZ1 homologous) domain (DPR; amino acids 91-223) that shares homology to the SET chromatin remodelling domain 16, 17 , induced brown fat cell differentiation from myoblasts. In Relative gene expression contrast, a mutant allele lacking zinc finger domain-1 (DZF-1; amino acids 224-447) completely lost its adipogenic function. The brown fat gene program was also induced by both wild-type and DPR, but not by DZF-1 ( Supplementary Fig. 2 ). To avoid comparing proteomic analyses of complexes from cells of very different phenotypes, we expressed all three PRDM16 forms in bona fide brown fat cells. PRDM16 complexes were then immunopurified to apparent homogeneity (Fig. 1c) , and subjected to high-resolution 'shotgun' sequencing by liquid chromatography with tandem mass spectrometry (LC-MS/MS) 18 . In total, 49 proteins were identified in differentiation-competent PRDM16 complexes, but only eight of these (Bclaf1, Zfp655, p53 (also known as Trp53), Cebpb, Zcchc8, Zkscan3, Zfp143 and Vezf1) are known or predicted transcription factors (Supplementary Table 1 ). Because we have assumed that the expression of a key initiating transcription factor would not be extinguished during the brown fat cell adipogenesis, and as PRDM16 is highly enriched in BAT relative to white adipose tissue (WAT) 13 , we asked whether any of these factors were similarly enriched in BAT. As shown in Fig. 1d , the expression of only Cebpb (C/EBP-b) was co-enriched with PRDM16 in BAT versus WAT. In addition, C/EBP-b protein was enriched in BAT, and further induced by cold exposure (Supplementary Fig. 3 ). Notably, both primary and immortalized myoblasts express C/EBP-b at similar levels to those seen in preadipocytes ( Supplementary Fig. 4 ), where this factor is thought to have a very important role in adipogenesis 19, 20 . Our analyses have therefore been focused on C/EBP-b and its function in complex with PRDM16.
Brown fat cells express three forms of C/EBP-b, two active forms, named LAP (liver-enriched transcriptional activator protein) and a dominant-negative form, LIP (liver-enriched transcriptional inhibitory protein) 21 ( Fig. 1e, left) . Notably, PRDM16 preferentially bound to LAP, but not to LIP ( Supplementary Fig. 6 ). This interaction is likely to be direct through the two zinc finger domains, because the zinc finger domains of the purified glutathione S-transferase (GST)-fused PRDM16 bound to in vitro translated C/EBP-b ( Supplementary Fig. 7 ). We also addressed whether PRDM16 could affect the transcriptional activity of C/EBP-b. Because C/EBP-b is known to induce Pgc1a (also known as Ppargc1a) gene expression 22 , we performed a luciferase reporter assay using the 22 kilobase (kb) Pgc1a promoter where the C/EBP-binding sites have been characterized 22 . As shown in Fig. 1f , the expression of PRDM16 and C/EBP-b synergistically stimulated Pgc1a promoter activity. These data suggest that PRDM16 forms a transcriptional complex with active forms of C/EBP-b by direct interaction, and regulates their transcriptional activity.
To examine the functional role of the interaction between PRDM16 and C/EBP-b in the myoblast to brown fat conversion, retroviruses expressing a short hairpin (sh) scrambled control RNA (scr), or shRNAs targeting C/EBP-b (shb-1 and shb-2) were transduced together with PRDM16 or an empty vector into C2C12 myoblasts (Fig. 2a) . As shown in Fig. 2b , knockdown of C/EBP-b significantly blunted the induction of Pparg2 expression by PRDM16 in undifferentiated C2C12 myoblasts. Consistent with this result, Oil Red O staining showed that depletion of C/EBP-b blunted the adipogenesis induced by PRDM16 (Fig. 2c) . Furthermore, induction of brown-fat-selective genes including Pgc1a, Ucp1, Elovl3 and Cox7a1 were completely or partially blocked by knockdown of C/EBP-b, correlating with the knockdown efficacy (Fig. 2d) . In addition, we ectopically expressed LIP, a dominant-negative form of C/EBP-b, and this also significantly blunted PRDM16-induced adipogenesis and brown-fat-selective gene expression (Supplementary Fig. 8) .
Next, we took a systematic approach to determine what fraction of the PRDM16-regulated genes requires C/EBP-b at the initiating step of the myoblast to brown fat conversion. To this end, RNAs from undifferentiated C2C12 myoblasts expressing PRDM16 or control together with scr or shb-1, maintained under conditions nonpermissive for differentiation, were subjected to Affymetrix microarray analysis. As shown in Fig. 2e , 316 genes were significantly increased or reduced by PRDM16 (.twofold, P , 0.05), which were clustered into four groups: (1) genes increased by PRDM16 in a C/EBP-b-dependent manner, (2) genes increased by PRDM16 in a C/EBP-b-independent manner, (3) genes repressed by PRDM16 in a C/EBP-b-dependent manner, and (4) genes repressed by PRDM16 in a C/EBP-b-independent manner. The expression of a subset of genes identified by microarray analyses was validated by PCR with reverse transcription (RT-PCR) (Supplementary Fig. 9) . Notably, most genes activated by PRDM16 before differentiation (62 out of 95, 65.3%) indeed required C/EBP-b, whereas most of the repressed genes (210 out of 221, 95.0%) were not grossly altered by C/EBP-b depletion.
We explored further the genetic requirement for C/EBP-b in brown fat development by analysing C/EBP-b-deficient embryos. Defects in BAT of C/EBP-b-null newborn or adult mice have been described, although the reported phenotype was inconsistent 23, 24 . Because a large number of these embryos died within the first 24 h after birth 23, 25 , we have re-examined this issue in late gestation (stage embryonic day (E)18.5). This should permit a clearer separation of developmental changes in the BAT, as opposed to those that might occur secondarily to abnormalities in other tissues after birth. As shown in Fig. 2f , haematoxylin and eosin staining showed that brown fat cells in knockout embryos contained significantly less lipid droplets than those in wild-type embryos, suggesting defects in brown fat development per se (Fig. 2f, top) . Moreover, UCP1 expression was severely reduced in knockout embryos (Fig. 2f, bottom) , consistent with the results described previously 23 . We also conducted a definitive molecular characterization of the BAT from wild-type and knockout embryos. Notably, BAT from C/EBP-b-knockout mice nearly phenocopied that from PRDM16-knockout mice at the gene expression level; that is, a broad reduction of BAT-selective gene expression, and a broad induction of the skeletal muscle gene expression (Fig. 2g) . Together, these data indicate that the PRDM16-C/EBP-b transcriptional complex specifically has a critical role in the initiation of myoblast to brown fat switch. This strongly suggests that PRDM16 acts in Myf5-positive myoblastic precursors, at least in part, by coactivation of C/EBP-b to induce the expression of Pparg and Pgc1a. Subsequently, PRDM16 co-activates PPARc and PGC-1a by direct binding events, which drives a complete brown fat differentiation program ( Supplementary Fig. 10 ).
This mechanistic model suggests a critical question: are the two factors sufficient to reconstitute a brown fat program in naive cells? To this end, PRDM16 and C/EBP-b were ectopically expressed in mouse embryonic fibroblasts (MEFs) or primary skin fibroblasts with no inherent adipose or brown fat character. As shown in Fig. 3a , Pparg2 messenger RNA expression was synergistically induced by PRDM16 and C/EBP-b in a dose-dependent manner in undifferentiated fibroblasts. After 6-8 days under adipogenic conditions, both MEFs and skin fibroblasts expressing these two factors uniformly differentiated into lipid-filled adipocytes, as shown by Oil Red O staining (Fig. 3b) . The single factors alone were not sufficient to robustly stimulate the differentiated state. Gene expression studies showed that PRDM16 and C/EBP-b powerfully induced mRNA levels of brown fat genes including Cox7a1 (70-fold), Cox8b (260-fold), Elovl3 (16-fold) and Cidea (170-fold) to levels comparable with or even higher than those seen in bona fide immortalized brown fat cells (Fig. 3c) . Notably, as in authentic brown fat cells, mRNA level of thermogenic genes such as Pgc1a and Ucp1 were further enhanced by cyclic AMP treatment (Fig. 3d) . The mechanism underlying the augmentation of cAMP effects in the engineered brown fat cells remains unknown. To our surprise, the mRNA levels of those genes at the basal state were activated to levels seen in cAMP-stimulated brown fat cells. Furthermore, the two factors were able to induce the brown fat gene program from primary mouse skin fibroblasts (Fig. 3e) and human skin fibroblasts isolated from newborn foreskin (Supplementary Fig. 11 ). An important characteristic of brown fat cells is their extraordinarily high rates of respiration, particularly uncoupled respiration in response to cAMP. As shown in Fig. 3f , engineered brown fat cells induced by these two factors have significantly higher levels of total and uncoupled respiration than control cells, by 4.4-and 6.5-fold, respectively, at the basal state. It is notable that the engineered cells have greater basal respiration, both total and uncoupled, than bona fide brown fat cells. However, whereas the bona fide brown fat cells can increase both total and uncoupled respiration further (by 85% and 90%, respectively) in response to cAMP, engineered brown fat cells already seem to be at their maximal respiration. That these cells are responsive to cAMP is shown by the fact that expression of thermogenic genes, such as such as Pgc1a and Ucp1, are induced by cAMP treatment (Fig. 3d) . Hence, some other aspect of the respiratory apparatus, unknown at this point, seems to be limiting in the engineered brown fat cells.
The finding that the combination of PRDM16 and C/EBP-b is sufficient to reconstitute a near complete brown fat program offers an opportunity for controlling brown fat levels and function in vivo. We conducted transplantation studies, as originally developed by Green and Kehinde 26 , using undifferentiated MEFs expressing vector, PRDM16, C/EBP-b, or a combination of the two factors. As shown by haematoxylin and eosin staining (Fig. 4a) , the cells expressing vector or PRDM16 or C/EBP-b alone did not form visible fat tissues. In contrast, the cells expressing both PRDM16 and C/EBP-b formed very distinct fat pads in vivo. Notably, at high magnification, the engineered fat tissue induced by the two factors contained 'multilocular' fat cells, a morphological characteristic of brown fat in vivo (Fig. 4b) . The population of multilocular fat cells (area 1) is mixed with regions of 'unilocular' fat cells (area 2). Notably, immunohistochemical analyses showed that the engineered adipose tissue was UCP1-positive in both the multilocular and unilocular fat cells (Fig. 4c) .
To characterize the activity of engineered brown fat tissue in vivo further, we used positron emission tomography (PET) with fluorodeoxyglucose ( 18 FDG), which has recently been used to detect active BAT in adult humans [4] [5] [6] [7] . This technique measures glucose uptake, with brown fat functioning in vivo as an active 'sink' for glucose. To this end, we engineered two adipose tissues with similar sizes in the same nude mice: a 'brown' fat tissue induced by PRDM16 and C/EBP-b, and a 'white' fat tissue induced by PPARc alone as a control (Supplementary Fig. 12a ). The induction of BAT-selective genes by PRDM16 and C/EBP-b was confirmed in the cultured cells by RT-PCR ( Supplementary Fig. 12b ). As shown in Fig. 4d , PET scanning detected a signal in mice from the engineered BAT. To enhance the sensitivity and specificity of the PET signal from the engineered fat tissues, the skin with these fat tissues attached was removed and scanned. The combination of computed tomography image (Fig. 4e , left) and PET image (Fig. 4e, right) clearly showed that the PET signal was detected from the engineered BAT, but not from the engineered WAT. These results indicate that the engineered brown fat cells function as a sink for active glucose disposal. Given the incredible capacity of BAT to dissipate stored chemical energy and thus counteract obesity, we are optimistic that the PRDM16 pathway can be used to drive brown fat development in vivo in a therapeutic setting. Certainly natural or synthetic compounds that can induce PRDM16 in white fat precursors or in myoblastic cells could have great value in human metabolic disease. Alternatively, as shown here, autologous transplantation of engineered brown fat induced by PRDM16 and C/EBP-b in amounts that are both clinically acceptable and therapeutically useful may well be possible. Future experiments must define the optimal conditions to achieve maximal angiogenesis, innervation and resulting energy expenditure from autologous transplants.
METHODS SUMMARY
Cell culture. Immortalized brown fat cells have been described previously 27 . Mouse embryonic fibroblasts were isolated from E13.5 C57/Bl6 embryos, and immortalized according to the established methods 28 . R2F primary skin fibroblasts isolated from human newborn foreskin were a gift from J. G. Rheinwald and cultured following the methods described elsewhere 29 . Adipocyte differentiation in fibroblasts was induced with medium containing 5 mM dexamethasone, 850 nM insulin, 1 nM T3 and 1 mM rosiglitazone. Identification of the PRDM16 transcriptional complex. Immortalized brown fat cells stably expressing Flag-tagged PRDM16 were homogenized to prepare nuclear extracts. The nuclear extracts were incubated with Flag M2 agarose (Sigma), washed in a binding buffer, and eluted by incubating with Flag peptide 12 .
The immunoprecipitated proteins were digested by trypsin and subjected to reverse-phase LC-MS/MS, using a high-resolution hybrid mass spectrometer (LTQ-Orbitrap, Thermo Scientific) with TOP10 method LETTERS MEFs, transduced with retroviral PRDM16 and/or C/EBP-b, were implanted subcutaneously into 7-9-week-old male nude mice (NCr-Foxn1 nu ) 13, 26 . For PET scanning studies, MEFs expressing retroviral PPARc were implanted as control. After 4-6 weeks, fat pads were dissected for histological analysis. MicroPET/ computed tomography (CT) scanning was performed using the Mosaic HP microPET in conjunction with the microCT of the NanoSPECT/CT (Philips), 60 min after the injection of 18 
FDG.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
